Nebenwirkungen · Mysimba
Mysimba 8 mg/90 mg prolonged-release tablets · Abschnitt 4.8 · PDF-Seite 13–14
HOS-130355 · Präparat HOS-096899
13 Hepatobiliary disorders Uncommon Cholecystitis ALT increased AST increased Hepatic enzyme increased Rare Drug induced liver injury Not known Hepatitis Skin and subcutaneous tissue disorders Common Hyperhidrosis Pruritus Alopecia Rash Not known Acne Erythema multiforme and Stevens Johnson syndrome Cutaneous lupus erythematosus Systemic lupus erythematosus syndrome aggravated Acute generalised exanthematous pustulosis (AGEP) Musculoskeletal and connective tissue Rare Jaw pain disorders Not known Arthralgia Groin pain Myalgia Rhabdomyolysis Renal and urinary disorders Uncommon Blood creatinine increased Rare Micturition urgency Not known Dysuria, Pollakiuria Urinary frequency and/or retention Reproductive system and breast Uncommon Erectile Dysfunction disorders Rare Irregular menstruation Vaginal haemorrhage Vulvovaginal dryness General disorders and administration Common Fatigue site conditions Feeling jittery Irritability Uncommon Asthenia Feeling abnormal Feeling hot Increased appetite Thirst Rare Chest pain Peripheral coldness Pyrexia Not known Chills Energy increased
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T14:58:00Z · SHA-256 8d91203fd1313606105ccfcfeb588970833594eb1edb4edb571e8c8ed61c515c · Passage c80010a0a01fd640eb042f6b32502f855d3b5d16eeea6843b2b247709c7c3da3 · Zeichen 8517–11644 im Abschnitt